Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + famotidine
- Development stage
- Unknown
- Lead developer
- Prometheus Laboratories
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
Aldesleukin + famotidine is an investigational combination regimen studied by the Leo W. Jenkins Cancer Center for the treatment of acute myeloid leukemia (AML). Aldesleukin is a recombinant form of human interleukin-2 (IL-2), a cytokine that acts as an immunotherapy by binding to the IL-2 receptor, thereby stimulating the proliferation and activation of T-cells and natural killer (NK) cells. In this specific clinical context, aldesleukin was administered as a daily pulse during the lymphocyte recovery phase following chemotherapy to enhance the immune system's ability to target residual leukemic cells. Famotidine, a histamine H2 receptor antagonist, was co-administered in the Phase II trial to evaluate its potential role in modulating the immune response or mitigating side effects during IL-2 therapy.
- Brand names
- ProleukinPepcid
- Other names
- Interleukin-2 + FamotidineIL-2 + FamotidinePulse Interleukin-2 with Famotidine
02
Targets
HRH2 (Histamine H2 Receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on aldesleukin + famotidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + famotidine.